These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12121797)

  • 1. Vaccinating first-year college students living in dormitories for Meningococcal disease: an economic analysis.
    Scott RD; Meltzer MI; Erickson LJ; De Wals P; Rosenstein NE
    Am J Prev Med; 2002 Aug; 23(2):98-105. PubMed ID: 12121797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis.
    Jackson LA; Schuchat A; Gorsky RD; Wenger JD
    Am J Public Health; 1995 Jun; 85(6):843-5. PubMed ID: 7762722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; Erickson L
    Vaccine; 2002 Jun; 20(21-22):2840-4. PubMed ID: 12102036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Meningococcal Serogroup B Vaccination in College-Aged Young Adults.
    Leeds IL; Namasivayam V; Bamogo A; Sankhla P; Thayer WM
    Am J Prev Med; 2019 Feb; 56(2):196-204. PubMed ID: 30573332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program.
    Bos JM; Rümke HC; Welte R; Postma MJ; Jager JC
    Vaccine; 2001 Oct; 20(1-2):202-7. PubMed ID: 11567765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal vaccination for adolescents? An economic evaluation in Victoria.
    Skull SA; Butler JR
    J Paediatr Child Health; 2001 Oct; 37(5):S28-33. PubMed ID: 11885733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal disease prevention and control strategies for practice-based physicians (Addendum: recommendations for college students). Committee on Infectious Diseases.
    Pediatrics; 2000 Dec; 106(6):1500-4. PubMed ID: 11099614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
    Si S; Zomer E; Fletcher S; Lee J; Liew D
    Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
    Christensen H; Hickman M; Edmunds WJ; Trotter CL
    Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry.
    Chung GS; Hutton DW
    PLoS One; 2020; 15(10):e0239926. PubMed ID: 33035260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for meningococcal disease in college students.
    Bruce MG; Rosenstein NE; Capparella JM; Shutt KA; Perkins BA; Collins M
    JAMA; 2001 Aug; 286(6):688-93. PubMed ID: 11495618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Bilukha OO; Rosenstein N;
    MMWR Recomm Rep; 2005 May; 54(RR-7):1-21. PubMed ID: 15917737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.
    de Soarez PC; Sartori AM; de Andrade Lagoa Nóbrega L; Itria A; Novaes HM
    Value Health; 2011 Dec; 14(8):1019-27. PubMed ID: 22152170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.
    Ginsberg GM; Block C; Stein-Zamir C
    Int J Public Health; 2016 Jul; 61(6):683-692. PubMed ID: 27105884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.